Philips: Building a Digital Health Ecosystem

Philips is a leading global health technology company and a key player in medical imaging, patient monitoring, and consumer health solutions. Known for its strong presence in hospitals and its trusted consumer brand, the company combines technological expertise with an integrated business model that connects devices, data, and software across the healthcare system. With a large installed base, ongoing investments in innovation, and a growing focus on improving efficiency in healthcare delivery, Philips aims to strengthen its position as a long term partner to health systems while driving profitable growth. The question remains: Does this health technology leader deserve a spot in your portfolio?

This is not a financial advice. I am not a financial advisor and I only do these post in order to do my own analysis and elaborate about my decisions, especially for my copiers and followers. If you consider investing in any of the ideas I present, you should do your own research or contact a professional financial advisor, as all investing comes with a risk of losing money. You are also more than welcome to copy me. 

For full disclosure, I should mention that I do not own any shares in Philips at the time of writing this analysis. If you would like to copy or view my portfolio, you can find instructions on how to do so here. If you want to purchase shares or fractional shares of Philips, you can do so through eToro. eToro is a highly user-friendly platform that allows you to get started on investing with as little as $50.

The Business

Philips was founded in 1891 in the Netherlands and has transformed from a diversified electronics manufacturer into a focused health technology company centered on improving patient outcomes and care efficiency. Today, Philips operates across three main segments: Diagnosis and Treatment, Connected Care, and Personal Health, covering everything from advanced imaging systems and minimally invasive treatment solutions to patient monitoring, health informatics, and consumer health products such as electric toothbrushes and baby monitors. Its core strategy is to move beyond selling individual devices and instead provide integrated healthcare solutions that combine hardware, software, data, and services into unified platforms. These platforms support the entire patient journey, from diagnosis in radiology departments and treatment in operating rooms to monitoring in hospitals and increasingly at home. Philips has built a global footprint with more than 2,5 million installed systems and relationships with around 80% of the world’s top hospitals, giving it a strong presence across multiple care settings. Revenue is generated through a mix of equipment sales, leasing, service contracts, software licenses, and recurring usage-based or subscription models, which aligns the company more closely with customers over time and increases visibility. In Diagnosis and Treatment, the company focuses on precision imaging and image guided therapies, where systems such as MRI, CT, ultrasound, and the Azurion platform are combined with AI enabled software to improve diagnostic accuracy and enable minimally invasive procedures, while also generating recurring revenue through service contracts, software upgrades, and per procedure usage models tied to devices and consumables. In Connected Care, Philips connects patient data across hospital and home settings through monitoring systems and informatics platforms, allowing clinicians to track patients continuously and act earlier, while monetizing these solutions through long term contracts, subscriptions, and as a service models such as enterprise monitoring, which embed Philips deeply into hospital operations. In Personal Health, the company leverages its brand and innovation capabilities to support everyday health and well being through consumer products, while increasingly building direct relationships and recurring revenue models through subscriptions and digital ecosystems, where connected devices such as Sonicare toothbrushes, grooming products, and baby monitors integrate with apps that provide personalized insights and coaching, and where recurring sales are supported through subscriptions for consumables like brush heads and blades as well as direct to consumer channels. A defining characteristic of Philips’ business model is its emphasis on platform integration, where imaging systems, monitoring devices, software, and data analytics are combined into cohesive ecosystems that deliver both clinical and operational value to customers. Philips’ competitive moat is built on a combination of high switching costs, technological integration, scale, and deep customer relationships.  Its platforms are deeply embedded in hospital infrastructure and clinical workflows, making them difficult and costly to replace once installed, as customers rely not only on the hardware but also on the associated software, data integration, training, and ongoing service contracts. The company’s large installed base acts as a powerful foundation for innovation, as it provides access to real world clinical data and usage patterns that can be used to improve products and develop new solutions, creating a feedback loop where more installations lead to more data, which leads to better solutions and stronger customer relationships. Philips also benefits from its ability to integrate multiple components of the healthcare value chain, combining imaging, monitoring, informatics, and AI into unified platforms that improve efficiency and outcomes, something few competitors can replicate at global scale. Its strong presence in leading hospitals further reinforces its position, as relationships with top tier institutions often influence purchasing decisions across broader healthcare systems. Continuous investment in innovation, supported by a large intellectual property portfolio and close collaboration with clinicians, helps ensure that its solutions remain aligned with real clinical needs. At the same time, the company’s shift toward software, services, and subscription based models strengthens the moat by increasing customer lifetime value and embedding Philips more deeply into both hospital workflows and consumer routines, making it harder for customers to switch once they are integrated into the ecosystem.

Management

Roy Jakobs serves as the CEO of Philips, a role he assumed in October 2022 after more than a decade with the company. He joined Philips in 2010 and has since held a range of senior leadership positions across multiple business units and geographies, including Head of Personal Health and Chief Business Leader of the Connected Care segment. His career at Philips has been marked by a focus on operational improvement, business transformation, and customer centric innovation, giving him a broad understanding of both the consumer and hospital facing sides of the business. Before joining Philips, Roy Jakobs built his career in international leadership roles across industrial and technology driven companies, where he developed experience in operations, supply chain management, and large scale organizational execution. This background has shaped his leadership approach, which places strong emphasis on discipline, accountability, and consistent delivery in complex global organizations. His ability to operate across different regions and business environments has been particularly relevant for Philips, given its global footprint and exposure to both developed and emerging healthcare systems. Roy Jakobs holds two master’s degrees, one in Business Administration and another in Marketing. Throughout his career, he has built a reputation as a pragmatic and execution focused leader who prioritizes clarity over complexity. He has described himself as a realist, emphasizing the importance of setting a clear direction and ensuring that strategy can be translated into actionable plans. This focus on execution is especially important in the healthcare technology industry, where regulatory requirements, product quality, and patient safety are critical and where operational missteps can have significant consequences. Since becoming CEO, Roy Jakobs has been leading a broad transformation of Philips aimed at simplifying the organization, improving execution, and restoring trust with customers and regulators. A central part of his strategy has been to reduce complexity by focusing resources on the company’s core segments, particularly areas such as Image Guided Therapy, Monitoring, and Ultrasound, where Philips has strong market positions and the potential to drive long term growth. At the same time, he has placed significant emphasis on strengthening quality systems, supply chain resilience, and operational discipline following the Respironics recall, recognizing that rebuilding credibility is essential for the company’s long term success. Another important element of Roy Jakobs’ leadership is his focus on turning Philips into a more integrated and platform driven company. By aligning the organization more closely around its core businesses and encouraging greater collaboration between business units, he aims to accelerate innovation while ensuring that new solutions are closely aligned with customer needs. This includes leveraging Philips’ installed base and data capabilities to drive more connected and software driven solutions, which can support both better clinical outcomes and more predictable recurring revenue streams. Roy Jakobs has also emphasized a culture of transparency and accountability, both internally and externally. He has acknowledged past challenges openly and has worked to establish clearer governance and performance metrics across the organization. This approach reflects an understanding that trust, particularly in healthcare, is built over time through consistent delivery and clear communication rather than short term promises. Given his deep knowledge of Philips, his operational background, and his clear focus on execution, simplification, and accountability, Roy Jakobs appears well positioned to lead the company through its current transition. His leadership is centered on restoring confidence, strengthening the core business, and positioning Philips as a more focused and resilient health technology company capable of delivering sustainable long term value.

The Numbers

The first number we will look into is the return on invested capital, also known as ROIC. We want to see a 10-year history, with all numbers exceeding 10% in each year. Looking at Philips, the numbers are clearly underwhelming. The company has only delivered ROIC above 10% in one of the past ten years, and returns deteriorated significantly following the Respironics recall, even turning negative in 2022. While there has been a gradual improvement in recent years, with ROIC recovering to around 6.3% in 2025, it still remains well below what would be considered an attractive level and far from management’s historical ambitions. Several structural and company specific factors explain why Philips has struggled to generate high returns on capital. First, the healthcare technology industry is inherently more capital intensive than many consumer businesses. Developing advanced imaging systems, monitoring equipment, and clinical software requires significant ongoing investment in research and development, manufacturing, and regulatory compliance. These investments are necessary to remain competitive but weigh on returns, especially when revenue growth or margins are under pressure. Second, Philips has historically operated a broad and somewhat complex portfolio, which has made it more difficult to allocate capital efficiently and achieve consistently high returns across all business units. This lack of focus has likely diluted overall ROIC over time. Third, the Respironics recall had a major impact on profitability and therefore on ROIC. Philips had to spend large amounts of money to fix or replace millions of affected devices, while also dealing with legal cases and regulatory requirements. These costs reduced profits significantly at a time when the company still had a large amount of capital invested in the business, which is why returns dropped sharply and even turned negative in 2022. In addition, the recall disrupted the Sleep and Respiratory Care business, which had previously been a strong contributor to profits, further weighing on overall returns. That said, there are signs that the situation is improving. ROIC has increased year over year since 2022, indicating that profitability is recovering and that management’s efforts to simplify the organization and improve execution are starting to have an effect. The company has become more focused, prioritizing areas such as Image Guided Therapy, Monitoring, and Ultrasound, where it has stronger competitive positions and better long term economics. At the same time, Philips is shifting its business model toward more software, services, and recurring revenue streams, which typically carry higher margins and require less incremental capital over time. If executed well, this transition should support higher returns going forward. Management has also been explicit about its ambitions. In its latest communication, the company stated that underlying or organic ROIC improved from mid single digit levels to low teens over the prior plan period, meaning that returns would have been significantly higher when excluding one off items such as the recall. Looking ahead, it is reasonable to expect ROIC to continue improving, but the pace and extent of that improvement remain uncertain. The underlying drivers are in place, including a stronger strategic focus, cost discipline, and a growing share of recurring revenue. However, Philips still operates in a competitive and capital intensive industry, and rebuilding margins after the recall will take time. Reaching mid teens ROIC is possible, but it will require consistent execution over several years. For now, the improving trend is encouraging, but returns remain below what would typically be considered attractive, meaning that Philips still has more to prove before it can be seen as a consistently high return business.

The next numbers are the book value + dividend. In my old format this was known as the equity growth rate. It was the most important of the four growth rates I used to use in my analyses, which is why I will continue to use it moving forward. As you are used to see the numbers in percentage, I have decided to share both the numbers and the percentage growth year over year. To put it simply, equity is the part of the company that belongs to its shareholders – like the portion of a house you truly own after paying off part of the mortgage. Growing equity over time means the company is becoming more valuable for its owners. So, when we track book value plus dividends, we’re essentially looking at how much value is being built for shareholders year after year. Philips’ equity has clearly been under pressure in recent years, with a peak in 2021 followed by consistent declines through to 2025. Unlike some companies where equity declines are driven by deliberate capital returns such as share buybacks, the movements in Philips’ equity are primarily explained by changes in profitability and one-off costs. When a company generates strong profits, equity increases because earnings are retained in the business. When profits are weak or negative, equity declines. This dynamic is the main driver behind Philips’ recent equity development. The most important factor has been the Respironics recall, which led to significant costs related to fixing and replacing devices, legal cases, and regulatory requirements. These costs reduced profits materially and therefore limited Philips’ ability to build equity. At the same time, parts of the business have faced weaker demand, including in China, which has further weighed on earnings. As a result, equity has declined over multiple years, reflecting a period where the company has struggled to generate consistent profitability. Another factor influencing equity is that Philips has been going through a broader transformation. The company has been simplifying its portfolio, focusing on its core healthcare segments, and investing in improving operations and quality systems. While these actions are necessary to strengthen the business long term, they can weigh on profits in the short term, which in turn affects equity growth. Importantly, the decline in equity in Philips’ case is not the result of a deliberate strategy to return large amounts of capital to shareholders, but rather a reflection of a period of weaker financial performance. This makes the development more concerning than in companies where equity declines are driven by strong cash flows and active capital returns. It highlights that Philips has been in a recovery phase rather than consistently building shareholder value over this period. Looking ahead, equity growth will depend on Philips’ ability to restore stable and improving profitability. Management has indicated that it aims to return to growth over time, supported by a more focused business, better execution, and a shift toward higher margin software and service revenues. If these efforts are successful, equity should begin to grow again. However, based on the most recent numbers, this recovery is not yet visible, and Philips still needs to demonstrate that it can consistently generate the level of earnings required to rebuild shareholder value over time.

Finally, we will analyze the free cash flow. Free cash flow, in short, refers to the cash that a company generates after covering its operating expenses and capital expenditures. I use levered free cash flow margin because I believe that margins offer a better understanding of the numbers. Free cash flow yield refers to the amount of free cash flow per share that a company is expected to generate in relation to its market value per share. Philips’ free cash flow has been quite volatile over the past decade, with periods of strong cash generation followed by sharp declines. The company delivered solid free cash flow in earlier years, and 2021 stands out as an exceptionally strong year, where both free cash flow and margins reached very high levels. However, this was followed by a sharp deterioration in 2022, where free cash flow turned negative and margins dropped significantly. Although there has been a recovery since then, both free cash flow and free cash flow margins remain below previous highs and have declined again in 2024 and 2025. Several factors explain this development. The most important one is the impact from the Respironics recall. Philips has had to pay large amounts of cash to fix and replace devices, settle legal cases, and meet regulatory requirements. These payments directly reduce free cash flow, which is why the company reported negative free cash flow in 2022 and still saw pressure in the years after. Even in 2025, free cash flow was held back by around €1 billion in cash payments related to settlements, which shows that the effects are still ongoing. Another factor is weaker profitability in certain periods. Free cash flow is closely linked to earnings, so when profits are under pressure, cash generation tends to decline as well. In addition, Philips has been investing in improving its operations, strengthening its supply chain, and focusing on its core healthcare businesses. These investments require capital expenditure, which reduces free cash flow in the short term but is intended to support future growth. Another factor is how much cash is tied up in the day to day running of the business. In some years, Philips has more cash tied up in inventory and in the timing of payments, which reduces free cash flow. In other years, the company has been able to free up cash by reducing inventory and improving how quickly it collects payments and pays suppliers. Management mentioned that Philips has freed up around €1 billion of cash in recent years by improving inventory levels, which has helped support free cash flow. However, this is not something that improves every year, and it can move up and down depending on how the business is managed. Looking ahead, management expects free cash flow to improve. The company is targeting €1,3 billion to €1,5 billion in 2026 and around €4,5 billion to €5 billion in total over the next three years. This improvement is expected to come from higher earnings, fewer one off costs related to the recall, and better execution across the business. At the same time, Philips plans to increase investments in the business to support growth and strengthen its operations, which may partly offset the improvement in free cash flow. Overall, the expectation is that free cash flow will become more stable and stronger as the company moves past the impact of the recall and improves profitability. Philips uses its free cash flow in a disciplined way. The first priority is to reinvest in the business, particularly in research and development and capital expenditures focused on high return opportunities such as Image Guided Therapy and Monitoring. The second priority is maintaining a stable dividend, with a target payout ratio of 40% to 50%. The company also uses free cash flow to strengthen its balance sheet and maintain a solid investment grade credit rating, which has already led to a reduction in leverage in recent years. In addition, Philips pursues selective acquisitions to strengthen its portfolio, while share buybacks are considered only when they make economic sense and fit within its broader capital allocation priorities. The free cash flow yield suggests that Philips is trading at a premium valuation. However, we will revisit valuation later in the analysis.

Debt

Another important aspect to consider is the level of debt. It is crucial to determine whether a business has manageable debt that can be repaid within a period of three years. We do this by dividing the total long term debt by earnings. The numbers show that Philips would need 6,9 years of earnings to pay off its debt. The debt to earnings ratio remains well above the three year threshold and is something that should be monitored closely. That said, it is encouraging to see that management is actively prioritizing debt reduction. Leverage has improved as earnings and cash flow have started to recover, indicating that the company is moving in the right direction. This suggests that while debt is still relatively high, the trend is improving, supported by better performance and a clear focus on strengthening the balance sheet.

Support the Blog

I want to keep the blog free and accessible for everyone. If you enjoy the content and would like to support it, you can buy me a cup of coffee through PayPal. Every little bit helps and is truly appreciated!

Risks

Recalls is a risk for Philips because the company operates in a highly regulated healthcare industry where product quality and patient safety are critical. The Respironics recall is a clear example of how serious and long lasting this risk can be. The issue first emerged in 2021, yet it is still affecting the business in 2026, which highlights how durable and persistent the consequences of a quality failure can be in healthcare. The most immediate impact has been financial. Philips has had to spend large amounts of money to fix and replace devices, handle legal cases, and meet regulatory requirements. These costs have reduced profits and free cash flow and have been one of the main reasons why returns have been weak in recent years. Even several years after the recall began, the company is still making payments and expects a continued impact going forward, which shows that these types of issues do not disappear quickly. The recall has also disrupted operations. Philips has had to redirect significant resources toward resolving the issue, improving product quality systems, and restructuring parts of the business. This has slowed execution and affected the performance of the Sleep and Respiratory Care segment, which was previously an important contributor to earnings. Because the business has not been able to operate normally for several years, the lost momentum is another hidden cost of the recall. Regulation adds another layer of risk. Philips is operating under strict oversight from U.S. regulators, which limits its ability to sell certain products in its most important market. Even years after the initial recall, the company is still working to meet all requirements. This delays the recovery and creates uncertainty around when the business can return to normal levels of revenue and profitability. It also shows how regulatory consequences can extend far beyond the initial issue. Reputation is also a key concern. Philips operates in a market where trust is essential, and the recall has damaged confidence among patients, healthcare providers, and regulators. In healthcare, trust takes years to build but can be lost quickly, and once lost, it can take a long time to regain. This means the impact of the recall is not only financial but also strategic, as it may affect future demand and competitive positioning. More broadly, the recall highlights a structural risk in Philips’ business model. When a company sells complex medical devices, any failure in quality, safety, or compliance can have wide ranging consequences across finances, operations, and reputation. As Philips continues to develop more advanced and connected solutions, including software and AI, the importance of getting quality right from the start becomes even greater, because the cost of failure can be both significant and long lasting.

Macroeconomic factors is a risk for Philips because the company operates globally and is therefore exposed to changes in economic conditions, government policies, and geopolitical tensions across many regions. A large part of Philips’ revenue comes from mature markets such as the United States and Europe, while growth markets are becoming increasingly important. At the same time, the company produces and sources many of its products in regions such as the United States, Europe, and China. This means that changes in economic conditions or political relationships between these regions can directly affect both demand and costs. One of the main risks comes from weaker economic growth. When economies slow down, governments and hospitals may delay investments in new medical equipment, which can reduce demand for Philips’ products. Healthcare spending is often more stable than other industries, but it is not immune to pressure. Hospitals facing budget constraints may postpone upgrades of imaging systems or reduce spending on new technology, which can impact Philips’ revenue growth. In addition, weaker consumer confidence can affect the Personal Health segment, where products such as electric toothbrushes and grooming devices are more discretionary. Geopolitical tensions also play an important role. Philips is exposed to ongoing uncertainty between major economies, particularly between the United States and China. Increasing protectionism, such as tariffs, trade restrictions, and local production requirements, can raise costs and make it more difficult to operate efficiently across borders. Management has already highlighted tariffs as a headwind, which means that these measures can directly reduce margins. At the same time, changing regulations and political decisions can create uncertainty and make long term planning more difficult. Another important factor is the structure of Philips’ supply chain. Because the company designs, manufactures, and sources products across multiple regions, disruptions to global trade can affect its ability to deliver products on time and at the expected cost. Conflicts such as the war in Ukraine or instability in the Middle East can lead to higher energy and transportation costs, delays in supply chains, and general market uncertainty. These disruptions can increase costs and reduce profitability if Philips is not able to pass those costs on to customers. China is a specific area of risk. The country has been an important growth market for Philips, but recent developments such as slower economic growth and anti corruption measures in the healthcare sector have affected demand. At the same time, China is working toward becoming more self sufficient in key technologies, including healthcare, which could increase competition for foreign companies like Philips over time.

Competition is a risk for Philips because the company operates in a highly competitive healthcare technology industry where innovation, pricing, and long term customer relationships are critical. Philips competes with large global players as well as more specialized companies across its different segments, including imaging, monitoring, and consumer health. This creates constant pressure to maintain technological leadership while also delivering attractive pricing and strong service levels. One of the main risks comes from pricing pressure. Hospitals and healthcare systems are often under financial constraints, which makes them highly focused on cost when making purchasing decisions. Competitors may offer similar products at lower prices or bundle solutions in ways that make it harder for Philips to win contracts. This can put pressure on margins, especially in large equipment deals where pricing negotiations are intense. Even if Philips maintains strong market positions, it may need to accept lower prices to remain competitive. Innovation is another key area of competition. The healthcare technology industry is evolving rapidly, with continuous advancements in imaging, software, and AI driven solutions. If competitors develop better or more cost effective technologies, Philips risks losing market share or being forced to increase its investment in research and development. This is particularly important in areas such as image guided therapy and connected care, where technological differentiation is a key driver of customer decisions. Falling behind in innovation could weaken Philips’ competitive position over time. Competition also affects Philips through its installed base and customer relationships. While the company benefits from strong long term relationships with hospitals, competitors are constantly trying to replace existing systems with their own solutions. If a competitor succeeds in winning a large contract, it can lead to the loss of not only equipment sales but also long term service and software revenue. Because these relationships are built over many years, losing even a few key customers can have a meaningful impact on future revenue streams. Another risk comes from regional competition, particularly in markets like China. Local companies are becoming more competitive and are often supported by government policies that favor domestic suppliers. This can make it more difficult for Philips to compete on both price and market access in these regions. Over time, this could limit growth opportunities in markets that are otherwise expected to contribute to future expansion.

Reasons to invest

Favorable structural trends is a reason to invest in Philips because the company operates in a healthcare market where demand is growing steadily over the long term, driven by demographic changes, rising disease prevalence, and increasing pressure on healthcare systems. Across the world, populations are aging, and older populations require more frequent and complex medical care. At the same time, chronic diseases such as cardiovascular conditions, respiratory illnesses, and neurological disorders are becoming more common. This leads to a structural increase in demand for diagnostics, monitoring, and treatment, which directly supports the markets in which Philips operates. A key driver behind this trend is the growing gap between demand for healthcare and the system’s ability to supply it. Healthcare systems are facing staff shortages, rising costs, and capacity constraints, which means they need to find ways to treat more patients with fewer resources. Philips is well positioned to benefit from this dynamic because its solutions are designed to improve efficiency and productivity. Its imaging systems, monitoring platforms, and software solutions help healthcare providers diagnose earlier, treat more effectively, and manage patients more efficiently. This makes Philips’ offerings increasingly relevant as hospitals look for ways to do more with less. Another important structural trend is the digitalization of healthcare. For many years, healthcare has been slower to adopt digital technologies, but this is now changing rapidly. Hospitals are increasingly investing in data, software, and AI to improve decision making and streamline workflows. Philips’ strategy of combining hardware, software, and data into integrated platforms fits directly into this shift. As healthcare systems adopt more connected and data driven solutions, Philips is positioned to benefit from both initial equipment sales and ongoing software and service revenue. There is also a clear trend toward shifting care outside the hospital. More patients are being treated at home or in outpatient settings, driven by both cost considerations and patient preferences. Philips has a strong presence in remote monitoring and home care solutions, which allows it to benefit from this shift. By enabling continuous monitoring and early intervention, the company’s solutions help reduce hospital stays and improve outcomes, which aligns well with the broader direction of healthcare systems. In addition, there is a growing focus on prevention and self care. Consumers are becoming more engaged in managing their own health, supported by digital tools and increased awareness of conditions such as sleep disorders and chronic diseases. This creates opportunities for Philips’ Personal Health segment, where products are increasingly connected and integrated into digital ecosystems. As more people seek to monitor and improve their health, demand for these types of solutions is likely to grow.

Leaner and more focused operations is a reason to invest in Philips because the company is actively transforming itself into a simpler, more efficient, and more disciplined organization that is better positioned to deliver profitable growth over time. In recent years, Philips has operated with a high level of complexity, including a broad portfolio, overlapping processes, and inefficiencies across functions. Under CEO Roy Jakobs, the company is addressing this by simplifying its structure, reducing costs, and focusing resources on the parts of the business with the strongest growth and margin potential. This shift is important because a simpler organization is typically easier to manage, more efficient, and better able to execute consistently. One of the clearest benefits of this transformation is improved profitability. Philips has already delivered more than €2,5 billion in cost savings over the past three years through productivity and efficiency initiatives, exceeding its original targets. These savings come from simplifying processes, reducing unnecessary costs, and improving how the company operates across its global footprint. Importantly, Philips is not stopping here and has launched a new €1,5 billion program to further improve efficiency over the coming years. This continued focus on cost discipline supports margin expansion and creates a stronger financial foundation for the business. Another important element is the simplification of the portfolio. Philips has been reducing low performing products and focusing more on its strongest business areas, such as Image Guided Therapy, Monitoring, and Ultrasound. By concentrating on these areas, the company can allocate capital more effectively and prioritize the opportunities that generate the highest returns. This also reduces operational complexity and allows management to focus on fewer, more impactful initiatives, which can improve execution and overall performance. Another key improvement is the way Philips is organized and managed. Decision making has been moved closer to the individual business units, which makes the organization faster and more responsive. Instead of relying on complex central structures, the company now operates with clearer accountability and better visibility into performance. This allows Philips to react more quickly to changes in demand, allocate resources more effectively, and capture growth opportunities when they arise. A faster and more agile organization is especially important in a dynamic global environment.

Innovation is a reason to invest in Philips because the company is increasingly focusing on developing high value, scalable solutions that support both growth and margin expansion over time. In the healthcare technology industry, innovation is not only about launching new products but also about improving clinical outcomes, increasing efficiency, and helping healthcare providers manage rising complexity. Philips has repositioned its innovation strategy to focus on fewer but more impactful products, which increases the likelihood that new launches will generate meaningful returns. One of the key strengths of Philips’ innovation approach is its focus on platforms rather than standalone products. The company is developing integrated solutions that combine hardware, software, and data, which can be scaled across customers and geographies. Examples include its Azurion platform in image guided therapy and IntelliVue in monitoring, which are not just devices but ecosystems that can generate ongoing revenue through upgrades, services, and software. This platform approach increases customer lifetime value and strengthens the company’s competitive position over time. Philips is also benefiting from a shift toward higher value and more advanced products. Recent innovations such as the helium free MRI systems, advanced CT scanners, and AI enabled navigation tools are designed to improve outcomes while also commanding higher prices. These types of products support a better mix, meaning that a larger share of revenue comes from premium offerings with higher margins. Management has highlighted that innovation is now contributing positively to margins, which suggests that new products are not only driving growth but also improving profitability. Philips has also changed how it develops new products. Innovation is now more closely tied to the needs of customers and end users, with a stronger focus on real clinical and consumer problems. By working closely with healthcare providers and consumers, the company is better able to design solutions that fit into existing workflows and deliver clear value. At the same time, Philips has become more disciplined in how it allocates resources, focusing on projects with the highest return potential and stopping those that do not scale. This improves the overall quality of its innovation pipeline. The company’s investment in research and development remains significant, at around 9% of revenue, which supports a steady flow of new products across all segments. At the same time, Philips is improving the efficiency of this spending by focusing on fewer, larger opportunities with clearer commercial potential. This combination of strong investment and better discipline increases the likelihood that innovation will translate into both growth and profitability.

Unlock Exclusive Seeking Alpha Discounts – Level Up Your Investing With Zero Risk

If you’ve been thinking about improving your investing process, this is the easiest way to start. These offers are only available through my links, and the Premium plan even comes with a 100% risk-free 7-day trial. Try everything for a week, and if it’s not for you, just cancel. You lose nothing.

1) Seeking Alpha Premium — Try It Free for 7 Days

Access the tools I personally use every day:

• Earnings transcripts

• Stock screeners

• Deep-dive analysis

• Portfolio tracking

• Market news with context that actually matters

Special Price: $269/year (normally $299) + 7-day free trial (for new users only)

Try Premium Free for 7 Days → HERE

(Explore everything — cancel anytime during the trial and pay $0.)

2) Alpha Picks — Proven Stock Ideas

This stock-picking service has delivered +287% returns vs. the S&P 500’s +77% (July 2022–Nov 2025).Great for investors who want curated, long-term picks backed by data.

Special Price: $449/year (normally $499)

Get Alpha Picks → HERE

(Although Alpha Picks doesn’t offer a free trial, its historical outperformance means the subscription can often pay for itself quickly if results persist. For many investors, the potential return far outweighs the upfront cost).

3) Premium + Alpha Picks Bundle — Best Value

Get both services together and save $159.Perfect if you want both broad tools and high-conviction stock ideas.

Special Price: $639/year (normally $798)

Get the Bundle → HERE

(This bundle doesn’t include a free trial, but it gives you both services at a $159 discount. You get Premium’s in-depth research plus Alpha Picks’ high-performing recommendations, making it the most comprehensive option for serious investors.)

Valuation

Now it is time to calculate the share price. I perform three different calculations that I learned at a Phil Town seminar. If you want to make the calculations yourself for this or other stocks, you can do so through the tools page on my website, where you have access to all three calculators for free.

The first is called the Margin of Safety price, which is calculated based on earnings per share (EPS), estimated future EPS growth, and estimated future price-to-earnings ratio (P/E). The minimum acceptable rate of return is 15%. Philips has had negative earnings in the past three years, so I chose to use an EPS of 0,93, which is from the year 2025. I have selected a projected future EPS growth rate of 7%. Finbox expects EPS to grow by 12,3% in the next five years, but I'm not as optimistic. Additionally, I have selected a projected future P/E ratio of 14, which is double the growth rate. This decision is based on Philips' historically higher price-to-earnings (P/E) ratio. Finally, our minimum acceptable rate of return has already been established at 15%. After performing the calculations, we determined the sticker price (also known as fair value or intrinsic value) to be €6,33. We want to have a margin of safety of 50%, so we will divide it by 2. This means that we want to buy Philips at a price of €3,17 (or lower, obviously) if we use the Margin of Safety price.

The second calculation is known as the Ten Cap price. The rate of return that a company owner (or stockholder) receives on the purchase price of the company essentially represents its return on investment. The minimum annual return should be at least 10%, which I calculate as follows: The operating cash flow last year was 1.162, and capital expenditures were 269. I attempted to analyze their annual report to calculate the percentage of capital expenditures allocated to maintenance. I couldn't find it, but as a rule of thumb, you can expect that 70% of the capital expenditures will be allocated to maintenance purposes. This means that we will use 188 in our calculations. The tax provision was 282. We have 951 outstanding shares. Hence, the calculation will be as follows: (1.162 – 188 + 282) / 951 x 10 = €13,21 in Ten Cap price.

The final calculation is referred to as the Payback Time price. It is a calculation based on the free cash flow per share. With Philips' free cash flow per share at €0,94 and a growth rate of 7%, if you want to recoup your investment in 8 years, the Payback Time price is €10,32.

Conclusion

I believe that Philips is an intriguing company with strong management. The company has built its moat on a combination of high switching costs, technological integration, scale, and deep customer relationships. ROIC has historically been underwhelming, but management expects ROIC to increase in the future and move above 10%. Free cash flow has been volatile as well, and the Respironics recall has weighed on cash generation in recent years, but as this issue is gradually resolved, free cash flow should improve going forward. Recalls are a risk for Philips because failures in product quality can lead to long lasting financial, operational, and regulatory consequences, as seen with the Respironics recall that began in 2021 and is still impacting the business in 2026. Such issues can reduce profits, disrupt operations, limit sales, and damage trust, making recovery both costly and time consuming. Macroeconomic factors are a risk for Philips because its global operations expose it to changes in economic conditions, government policies, and geopolitical tensions, which can affect both demand and costs. Slower growth, tariffs, and supply chain disruptions can reduce hospital spending, increase costs, and pressure margins, particularly given Philips’ exposure to key markets like the United States, Europe, and China. Competition is a risk for Philips because it operates in a highly competitive industry where rivals can pressure pricing, win contracts, and challenge its technological leadership. This can lead to lower margins, potential loss of market share, and reduced long term revenue, especially if competitors offer better or more cost effective solutions. Favorable structural trends are a reason to invest in Philips because long term demand for healthcare is growing due to aging populations, rising chronic diseases, and increasing pressure on healthcare systems. At the same time, trends such as digitalization, home based care, and a greater focus on prevention make Philips’ solutions increasingly relevant, supporting sustained growth over time. Leaner and more focused operations are a reason to invest in Philips because the company is simplifying its structure, reducing costs, and focusing on its most profitable segments, which supports better execution and higher margins. This transformation is already driving efficiency gains and should lead to more consistent performance and stronger profitability over time. Innovation is a reason to invest in Philips because the company is developing high value, scalable solutions that drive both growth and margin expansion over time. By focusing on integrated platforms, premium products, and more disciplined R&D, Philips is strengthening its competitive position while increasing the likelihood that innovation translates into higher profitability. While there are many things to like about Philips, I personally believe there are better options in the market, and therefore I will not be investing in Philips at this time.

My personal goal with investing is financial freedom. It also means that to obtain that, I do different things to increase my wealth. If you have some extra hours to spare each month, you can turn a few hours a week into a substantial amount of money in a few years. If you are interested to know how I do it, you can read this post.

I hope you enjoyed my analysis! While I can’t post about every company I analyze, you can stay updated on my trades by following me on Twitter. I share real-time updates whenever I buy or sell, so if you’re making your own investment decisions, be sure to follow along!

Some of the greatest investors in the world believe in karma, and to receive, you will have to give. If you appreciated my analysis and want to get some good karma, I would kindly ask you to donate a bit to shark and rays. These animals are very important for our ecosystem, and their numbers are dwindling. If you have a little to spare, no matter how little, I would appreciate it if you would donate a little here. Thank you.